Nasdaq

Codex DNA Demonstrates Simple, Scalable, and Cell-Free Approach to Rapid mRNA Vaccine Design and Development at World Vaccine Congress Washington 2022

SAN DIEGO, April 18, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced its speaker presentation for the World Vaccine ...
Seeking Alpha

Codex DNA Announces Plan to Change Corporate Name to Telesis Bio

SAN DIEGO, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (DNAY), a leader in automated multi-omic and synthetic biology solutions, today announced a plan to change its Company name to Telesis Bio.
Nasdaq

Codex DNA Announces Commercial Availability of Automated mRNA Synthesis Kit with Integrated Capping Technology for BioXp™ System

SAN DIEGO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced the commercial launch of its BioXp™ mRNA ...